Roivant par­lays a $450M chunk of eq­ui­ty in biotech buy­out, grab­bing a com­pu­ta­tion­al group to dri­ve dis­cov­ery work

New Roivant CEO Matt Gline has craft­ed an all-eq­ui­ty up­front deal to buy out a Boston-based biotech that has been toil­ing for sev­er­al years now at build­ing a su­per­com­put­ing-based com­pu­ta­tion­al plat­form to de­sign new drugs. And he’s adding it to the Erec­tor set of sci­ence op­er­a­tions that are be­ing built up to sup­port their net­work of biotech sub­sidiaries with an eye to grow­ing the pipeline in a play to cre­ate a new kind of phar­ma com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER